About Panoptes Pharma
Panoptes Pharma is a company based in Vienna (Austria) founded in 2013 was acquired by EyeGate in December 2020.. Panoptes Pharma has raised $1.62 million across 2 funding rounds from investors including Austria Wirtschaftsservice and EyeGate. Panoptes Pharma offers products and services including PP-001, Augentropfen, Injektionen, and Systemische Arzneimittel. Panoptes Pharma operates in a competitive market with competitors including Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others.
- Headquarter Vienna, Austria
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$1.62 M (USD)
in 2 rounds
-
Latest Funding Round
-
Investors
Austria Wirtschaftsservice
& 1 more
-
Employee Count
Employee Count
-
Acquired by
EyeGate
(Dec 21, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Panoptes Pharma
Panoptes Pharma offers a comprehensive portfolio of products and services, including PP-001, Augentropfen, Injektionen, and Systemische Arzneimittel. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats eye diseases like Uveitis and diabetic Retinopathy.
Provides treatment for eye conditions through topical application.
Delivers therapies for various medical issues via injection.
Offers treatments for conditions like erectile dysfunction.
Funding Insights of Panoptes Pharma
Panoptes Pharma has successfully raised a total of $1.62M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Last Round
-
First Round
First Round
(26 Sep 2013)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2015 | Amount | Series A - Panoptes Pharma | Valuation |
investors |
|
| Sep, 2013 | Amount | Seed - Panoptes Pharma | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Panoptes Pharma
Panoptes Pharma has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Austria Wirtschaftsservice and EyeGate. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Banking regulatory services are provided for Austrian financial institutions.
|
Founded Year | Domain | Location | |
|
Therapeutics and drug delivery systems for eye diseases are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Panoptes Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Panoptes Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Panoptes Pharma Comparisons
Competitors of Panoptes Pharma
Panoptes Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| domain | founded_year | HQ Location |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
|
| domain | founded_year | HQ Location |
Mobile SDK developed for app engagement and monetization strategies.
|
|
| domain | founded_year | HQ Location |
Gene therapies for ocular and neurodegenerative diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Panoptes Pharma
When was Panoptes Pharma founded?
Panoptes Pharma was founded in 2013.
Where is Panoptes Pharma located?
Panoptes Pharma is headquartered in Vienna, Austria.
Is Panoptes Pharma a funded company?
Panoptes Pharma is a funded company, having raised a total of $1.62M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1.62M, raised on Sep 26, 2013.
What does Panoptes Pharma do?
Panoptes Pharma was established in 2013 in Vienna, Austria, within the pharmaceutical sector. Small molecule-based treatments are developed for eye conditions with significant unmet needs, including autoimmune uveitis and inflammatory diseases. The lead candidate, PP-001, functions as a specific inhibitor of an enzyme in the de novo pyrimidine pathway and is undergoing preclinical trials for uveitis and viral conjunctivitis. Operations center on advancing these therapies through clinical development.
Who are the top competitors of Panoptes Pharma?
Panoptes Pharma's top competitors include Annexon, Alimera Sciences and MeiraGTx.
What products or services does Panoptes Pharma offer?
Panoptes Pharma offers PP-001, Augentropfen, Injektionen, and Systemische Arzneimittel.
Who are Panoptes Pharma's investors?
Panoptes Pharma has 2 investors. Key investors include Austria Wirtschaftsservice, and EyeGate.